Simpler HIV pill tested for older adults
NCT ID NCT05911360
Summary
This study is testing if switching to a simpler, two-drug HIV pill works as well as a three-drug pill for keeping the virus suppressed. It involves 205 people living with HIV who are 50 or older and have had their virus under control for at least a year. The main goal is to see if the simpler regimen is just as effective and safe after 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85015, United States
-
GSK Investigational Site
Bakersfield, California, 93301, United States
-
GSK Investigational Site
Palm Springs, California, 92262, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Miami, Florida, 33133, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33407, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
Decatur, Georgia, 30033, United States
-
GSK Investigational Site
Macon, Georgia, 31201, United States
-
GSK Investigational Site
Boston, Massachusetts, 02043, United States
-
GSK Investigational Site
Berkley, Michigan, 48072, United States
-
GSK Investigational Site
Detroit, Michigan, 48202, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Omaha, Nebraska, 68198, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89106, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27401, United States
-
GSK Investigational Site
Wilmington, North Carolina, 28401-7684, United States
-
GSK Investigational Site
Akron, Ohio, 44304, United States
-
GSK Investigational Site
Portland, Oregon, 97239, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Austin, Texas, 78705, United States
-
GSK Investigational Site
Innsbruck, 6020, Austria
-
GSK Investigational Site
Vienna, 1100, Austria
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Toronto, Ontario, M5G 2N2, Canada
-
GSK Investigational Site
Montreal, Quebec, H2L 1N9, Canada
-
GSK Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
GSK Investigational Site
Nice, 6202, France
-
GSK Investigational Site
Orléans, 45100, France
-
GSK Investigational Site
Paris, 75004, France
-
GSK Investigational Site
Freiburg im Breisgau, 79106, Germany
-
GSK Investigational Site
Hanover, 30625, Germany
-
GSK Investigational Site
München, 80336, Germany
-
GSK Investigational Site
Milan, 20142, Italy
-
GSK Investigational Site
Modena, 41100, Italy
-
GSK Investigational Site
Roma, 161, Italy
-
GSK Investigational Site
Torino, 10149, Italy
-
GSK Investigational Site
Mérida, 97070, Mexico
-
GSK Investigational Site
Monterrey, 64460, Mexico
-
GSK Investigational Site
Amsterdam, 1105 AZ, Netherlands
-
GSK Investigational Site
Rotterdam, 3079 DZ, Netherlands
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Porto, 4099-001, Portugal
-
GSK Investigational Site
Porto, 4200-319, Portugal
-
GSK Investigational Site
Vila Nova de Gaia, 4434-502, Portugal
-
GSK Investigational Site
Guadalajara, 19002, Spain
-
GSK Investigational Site
Manresa Barcelona, 08243, Spain
-
GSK Investigational Site
Sabadell Barcelona, 8208, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Liverpool, L7 8XP, United Kingdom
-
GSK Investigational Site
London, SE1 9RT, United Kingdom
-
GSK Investigational Site
London, SW7 2AZ, United Kingdom
Conditions
Explore the condition pages connected to this study.